Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically
- 1 March 1994
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 69 (3) , 572-576
- https://doi.org/10.1038/bjc.1994.104
Abstract
The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-1 given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response (CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was 3-5 months and additional courses of ten injections of IL-2 had no further effect.Keywords
This publication has 13 references indexed in Scilit:
- Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.1992
- Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.The Journal of Immunology, 1990
- INVIVO INTERLEUKIN 2-INDUCED ACTIVATION OF LYMPHOKINE-ACTIVATED KILLER-CELLS AND TUMOR CYTOTOXIC T-CELLS IN CERVICAL LYMPH-NODES OF PATIENTS WITH HEAD AND NECK TUMORS1990
- Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin-2 injected periiymphaticallyCancer, 1988
- Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.The Journal of Immunology, 1987
- Immunomodulators as local hormones: new insights regarding their clinical utilization.1985
- Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.The Journal of Immunology, 1985
- EVALUATION OF BLOCKING MECHANISMS AGAINST IMMUNOLOGICAL RESPONSES IN PATIENTS WITH LARYNGEAL CARCINOMAThe Laryngoscope, 1984
- Production of Leukocyte Migration Inhibition Factor by Lymphocytes of Larynx Cancer Patients Stimulated by Laryngeal Carcinoma Solubilized Membrane AntigensTumori Journal, 1982
- Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neckThe American Journal of Surgery, 1974